What is ImageneBio, Inc. (IMA) stock price today?

ImageneBio, Inc. (IMA) currently trades at $6.02 per share. The stock has a market capitalization of $65.21M and a P/E ratio of —x.

Is IMA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, ImageneBio, Inc. has a Smart Value Score of 29/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is 1.43.

What is ImageneBio, Inc.'s revenue and earnings?

ImageneBio, Inc. has trailing twelve-month (TTM) revenue of $800000.00 with profit margins of 0.00%. Earnings per share (EPS) is $-9.64.

Is ImageneBio, Inc. financially healthy?

ImageneBio, Inc.'s Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of 1.43 places it in the distress.

IMA

ImageneBio, Inc.

NASDAQ: IMA · HEALTHCARE · BIOTECHNOLOGY

$6.02

+1.52% today

Updated 2026-04-30

Market cap

$65.21M

P/E ratio

—

P/S ratio

81.51x

EPS (TTM)

$-9.64

Dividend yield

—

52W range

$4 – $18

Volume

0.4M

Market cap

$65.21M

P/E ratio

—

P/S ratio

81.51x

EPS (TTM)

$-9.64

Dividend yield

—

52W range

$4 – $18

Volume

0.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.3

Growth

6.5

Quality

2.5

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

1.4

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$16.00

+165.78%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy2 Buy0 Hold1 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.08x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z 1.43 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-7.22M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$15.62M	$9.16M	$3.50M	$800000.00	$800000.00
Net income	$-68.77M	$-68.17M	$-36.57M	$-45.35M	$-6.91M
EPS	—	—	—	—	$-9.64
Free cash flow	$-75.54M	$-80.16M	$-46.00M	$-47.84M	$-7.22M
Profit margin	-440.29%	-744.17%	-1,044.80%	-5,668.63%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
IMA	$65.21M	29	3.3	2.5	5.0	6.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

ImageneBio, Inc. trades at $6.02. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 1.43, it sits in the distress. TTM revenue stands at $800000.00.

Frequently asked questions

What is ImageneBio, Inc.'s stock price?

ImageneBio, Inc. (IMA) trades at $6.02.

Is ImageneBio, Inc. overvalued?

Smart Value Score 29/100 (Grade F, Strong Sell).

What is the price target of ImageneBio, Inc. (IMA)?

The analyst target price is $16.00, representing +165.8% upside from the current price of $6.02.

What is ImageneBio, Inc.'s revenue?

TTM revenue is $800000.00.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

1.43 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.inmagenebio.com

Quick metrics

P/S ratio81.51x

ROE-68.90%

Beta—

50D MA$5.84

200D MA$8.52

Shares out0.01B

Float0.01B

Short ratio—

Avg volume0.4M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

IMA vs LLY →IMA vs JNJ →IMA vs ABBV →Stock screener →